HeartBeam (Nasdaq:BEAT) announced today that it received FDA 510(k) clearance for its 12-lead electrocardiogram (ECG) ...
TipRanks on MSN
HeartBeam (NASDAQ: BEAT) secures FDA 510(k) clearance for 12-lead ECG synthesis software following successful appeal
Austin, Texas, United States, December 10th, 2025, FinanceWire HeartBeam (NASDAQ: BEAT), a medical technology company focused ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced ...
HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions, was featured in a ...
Beginning in February, Kern County will become the first in the state to equip all EMS providers with handheld, AI-enabled 12 ...
HeartBeam shares rise after FDA clears its 12-lead ECG software, boosting plans for a 2026 launch and expanded cardiac detection technology.
Santa Clara–based HeartBeam is developing a cable-free, credit-card-sized ECG recorder that captures 3D cardiac signals and synthesizes them into a diagnostic-quality 12-lead ECG. The platform’s ...
Unlike any single-lead or 6-lead consumer device, HeartBeam’s patented cable-free technology captures the heart’s electrical signals in three non-coplanar dimensions and synthesizes them into a ...
HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions, was featured in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback